New Oxford Textbook of Psychiatry

Much gratitude is due to the distinguished editors for bringing us the book, the many first-class authors for contributing their chapters and Oxford University Press for their excellent production. The book will, in my view, continue to occupy a dominant place in the international medical literature and, at least for the foreseeable future, could well turn out to be the most widely used and influential reference work of its kind in psychiatry.

Auteur
John R. Geddes is Professor of Epidemiological Psychiatry and Head of the Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. Nancy C. Andreasen is Professor of Psychiatry and Andrew H. Woods Chair of Psychiatry, Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, USA. Guy M. Goodwin is Senior Research Fellow, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.

Texte du rabat

Over its two editions, The New Oxford Textbook of Psychiatry has come to be regarded as one of the most popular and trusted standard psychiatry texts among psychiatrists and trainees.

Contenu

• Section 1: The subject matter and approach to psychiatry

• 1: Kay Redfield Jamison and Adam Ian Kaplin: The patient's perspective

• 2: Nicole Votruba, Mirja Koschorke, and Graham Thornicroft: Public attitudes and the challenge of stigma

• 3: Crick Lund, Dörte Bemme, and Judy Bass: Global mental health

• 4: Pierre Pichot: The history of psychiatry as a medical specialty

• 5: Ilina Singh, Julian Savulescu, and Matthew L. Baum: A new ethics for 21st century psychiatry

• 6: Hans-Jürgen Möller: Foundations of phenomenology / descriptive psychopathology

• 7: Darrel A. Regier, David P. Goldberg, Geoffrey M. Reed and Bedirhan T. Ustun: DSM-5 and ICD-11 classifications

• 8: Charles A. Sanislow, Sarah E. Morris, Jennifer Pacheco, and Bruce N. Cuthbert: The National Institute of Mental Health Research Domain Criteria: An alternative framework to guide psychopathology research

• 9: Andrea Cipriani, Stefan Leucht, and John R. Geddes: Application of research evidence in clinical practice

• 10: Guy M. Goodwin, Joseph Zohar, and David J. Kupfer: A neuroscience based nomenclature for psychotropic drugs

• Section 2: The scientific basis of psychiatric aetiology and treatment

• 11: Karl Zilles and Nicola Palomero-Gallagher: Neuroanatomy

• 12: Mark Woolrich, Mark Jenkinson, and Clare Mackay: Neuroimaging technologies

• 13: Olaf Sporns: The connectome

• 14: Trevor Sharp: Neurotransmitters and signalling

• 15: Juan C. Leza, Javier R. Caso, and Borja García-Bueno: Psychoneuroimmunology

• 16: Caleb Webber: Functional genomics

• 17: Anna Christina Nobre: Cognitive neuroscience: Principles and methods

• 18: Verena Heise, Enik? Zsoldos, and Klaus P. Ebmeier: Ageing and the human brain

• 19: Helen S. Mayberg, Andrea Cowell, and Patricio Riva Posse: Development of brain stimulation

• 20: Amy Chan and Rob Horne: Adherence to treatment in psychiatry

• Section 3: Intellectual disabilities

• 21: Anthony J. Holland: Core dimensions of intellectual disabilities

• 22: Sally-Ann Cooper: Epidemiology and course of intellectual disabilities

• 23: Judith L. Rapoport, Dale Zhou, and Kwangmi Ahn: Aetiology of intellectual disability: General issues and prevention

• 24: José-Luis Ayuso-Mateos and Cary S. Kogan: Management and treatment of intellectual disability

• Section 4: Autism spectrum disorders

• 25: Fred R. Volkmar and Scott L. J. Jackson: Core dimensions of autism spectrum disorders

• 26: Emily J. H. Jones: Basic mechanisms and treatment targets for autism spectrum disorders

• 27: Charles R. Newton: Epidemiology of autism

• 28: Abha R. Gupta, Thomas V. Fernandez, and Ellen J. Hoffman: Genetics of autism spectrum disorders

• 29: Christine Eckera and Declan Murphy: Imaging of autism spectrum disorders

• 30: Emily Simonoff: Management and treatment of autism spectrum disorders

• Section 5: Attention deficit and hyperactivity disorder

• 31: Eric Taylor: Core dimensions of attention deficit hyperactivity disorder

• 32: Barbara Franke and Jan K. Buitelaar: Basic mechanisms and treatment planning / targets for attention deficit hyperactivity disorder

• 33: Guilherme V. Polanczyk: Epidemiology of attention deficit hyperactivity disorder and the implications for its prevention

• 34: Kate Langley and Anita Thapar: Genetics of attention deficit hyperactivity disorder

• 35: Philip Shaw and Eszter Szekely: Insights from neuroanatomical imaging into attention deficit hyperactivity disorder throughout the lifespan

• 36: Alessandro Zuddas and Sara Carucci: Management and treatment of attention deficit hyperactivity disorder

• Section 6: Motor disorders

• 37: Davide Martino and Antonella Macerollo: Neurodevelopmental motor disorders

• Section 7: Delirium, dementia, and other cognitive disorders

• 38: Noel J. Buckley and George K. Tofaris: Pathways of neurodegeneration underlying dementia

• 39: Ravi S. Bhat and Kenneth Rockwood: Delirium

• 40: Ivan Koychev and John Gallacher: Alzheimer's disease

• 41: Akitoshi Takeda and Bruce Miller: Frontotemporal dementias

• 42: Akin Nihat, TzeHow Mok, and John Collinge: Prion disease

• 43: Anto P. Rajkumar and Dag Aarsland: Dementia with Lewy bodies

• 44: Michele Hu and Fahd Baig: Dementia in Parkinson's disease

• 45: Russell L. Margolis: Dementia due to Huntington's disease

• 46: Joanne A. Byars and Ricardo E. Jorge: Vascular cognitive impairment

• 47: Christian Lepage, Inga K. Koerte, Vivian Schultz, Michael J. Coleman, and Martha E. Shenton: Traumatic brain injury

• Section 8: Substance use disorders

• 48: Trevor W. Robbins and Barry J. Everitt: Substance use disorders and the mechanisms of drug addiction

• 49: Yann Le Strat, Nicolas Ramoz, and Philip Gorwood: Genetics of substance use disorders

• 50: Wim van den Brink and Falk Kiefer: Alcohol use disorder

• 51: Michael Farrell, Briony Larance, and Courtney Breen: Opiates: Heroin, methadone, buprenorphine

• 52: David J. Castle: Cannabis and mental illness

• 53: Adam R. Winstock and Remy Flechais: Stimulants, ecstasy, and other party drugs

• 54: Adam Winstock and James Rucker: Psychedelics and dissociative substances

• 55: Marcus Munafo and Meryem Grabski: Tobacco addiction

• 56: Julia M. A. Sinclair and Anne Lingford-Hughes: Co-morbidity of substance use and psychiatric disorders

• Section 9: Schizophrenia and psychotic disorders

• 57: Nancy C. Andreasen: The core dimensions of schizophrenia

• 58: Assen Jablensky: Epidemiology and course of schizophrenia

• 59: Kimberley M. Kendall, James T. R. Walters and Michael C. O Donovan: Genetics of schizophrenia

• 60: Andreea O. Diaconescu, Sandra Iglesias, and Klaas E. Stephan: Structural and functional neuroimaging of schizophrenia

• 61: William S. Stone, Stephen V. Faraone and Ming T. Tsuang: Schizoaffective and schizotypal disorders / acute and transient psychotic disorders

• 62: Andreas Marneros: Delusional disorders

• 63: Emre Bora, Mahesh Jayaram, and Christos Pantelis: Prevention and early intervention in psychotic disorders

• 64: Herbert Y. Meltzer and William V. Bobo: Antipsychotic and anticholinergic drugs

• 65: Joseph P. McEvoy, Kammarauche Asuzu, Daniel W. Bradford, Oliver Freudenreich, and Katherine Moyer: The treatment and management of patients with schizophrenia

• Section 10: Mood disorders

• 66: S. Nassir Ghaemi and Sivan Mauer: Diagnosis, classification and d…